XML 28 R17.htm IDEA: XBRL DOCUMENT v3.5.0.2
Segment Reporting
 6 Months Ended
Jun. 30, 2016
Segment Reporting [Abstract]  
SEGMENT REPORTING
SEGMENT REPORTING

In 2016 and 2015, we identified six operating segments including Interventional Cardiology, Peripheral Interventions, Rhythm Management, Endoscopy, Urology and Pelvic Health, and Neuromodulation. Our reportable segments represent an aggregate of operating segments based on the criteria prescribed in FASB ASC Topic 280 - Segment Reporting. We have three reportable segments comprised of Cardiovascular, Rhythm Management, and MedSurg. Each of our reportable segments generates revenues from the sale of medical devices. We measure and evaluate our reportable segments based on segment net sales and operating income, excluding the impact of changes in foreign currency. Sales generated from reportable segments, as well as operating results of reportable segments, are based on internally-derived standard currency exchange rates, which may differ from year to year, and do not include intersegment profits. As needed, we restate segment information for the prior period based on our internally-derived standard currency exchange rates used for the current period in order to remove the impact of foreign currency exchange fluctuation. We exclude from segment operating income certain corporate-related expenses and certain charges or credits that our chief operating decision maker considers to be non-recurring and/or non-operational, such as amounts related to intangible asset impairment charges, acquisition- and divestiture-, litigation-, restructuring- and restructuring-related net charges and credits; pension termination charges; and amortization expense. Although we exclude these amounts from segment operating income, they are included in reported consolidated operating income (loss) and are included in the reconciliation below.

A reconciliation of the totals reported for the reportable segments to the applicable line items in our accompanying unaudited condensed consolidated statements of operations is as follows:
 
 
Three Months Ended
June 30,
 
Six Months Ended
June 30,
(in millions)
 
2016
 
2015
 
2016
 
2015
 
 
 
 
 
 
 
 
 
Net sales
 
 
 
 
 
 
 
 
Interventional Cardiology
 
$
635

 
$
567

 
$
1,248

 
$
1,108

Peripheral Interventions
 
278

 
245

 
542

 
477

Cardiovascular
 
913

 
812

 
1,790

 
1,585

 
 
 
 
 
 
 
 
 
Cardiac Rhythm Management
 
512

 
490

 
983

 
973

Electrophysiology
 
64

 
60

 
128

 
121

Rhythm Management
 
576

 
550

 
1,111

 
1,094

 
 
 
 
 
 
 
 
 
Endoscopy
 
390

 
352

 
755

 
680

Urology and Pelvic Health
 
270

 
142

 
513

 
272

Neuromodulation
 
139

 
125

 
264

 
241

MedSurg
 
799

 
619

 
1,532

 
1,193

Net sales allocated to reportable segments
 
2,288

 
1,981

 
4,433

 
3,872

Impact of foreign currency fluctuations
 
(162
)
 
(138
)
 
(343
)
 
(261
)
 
 
$
2,126

 
$
1,843

 
$
4,090

 
$
3,611

 
 
 
 
 
 
 
 
 
Income (loss) before income taxes
 
 
 
 
 
 
 
 
Cardiovascular
 
$
294

 
$
247

 
$
593

 
$
483

Rhythm Management
 
97

 
78

 
187

 
155

MedSurg
 
262

 
188

 
502

 
355

Operating income allocated to reportable segments
 
653

 
513

 
1,282

 
993

Corporate expenses and currency exchange
 
(155
)
 
(105
)
 
(290
)
 
(188
)
Intangible asset impairment charges; acquisition- and divestiture-, restructuring- and restructuring-related net charges; litigation-related net charges and credits; and pension termination charges
 
(697
)
 
(73
)
 
(762
)
 
(333
)
Amortization expense
 
(135
)
 
(116
)
 
(271
)
 
(229
)
Operating income (loss)
 
(334
)
 
219

 
(41
)
 
243

Other expense, net
 
(63
)
 
(114
)
 
(128
)
 
(189
)
Income (loss) before income taxes
 
$
(397
)
 
$
105

 
$
(169
)
 
$
54